PD L1 News and Research

RSS

New potential target for treating metastasized oral malignant melanoma in dogs

Scientists have shown that the biological molecule PD-L1 is a potential target for the treatment of metastasized oral malignant melanoma in dogs.

23 Apr 2021

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

22 Apr 2021

Aneuploidy testing can be key in determining optimal treatment for lung cancer patients

Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.

12 Apr 2021

New research could rescue failed immunotherapies for treating solid tumors

New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.

7 Apr 2021

High expression of cell death genes may increase risk of early death from lung cancer

Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.

5 Apr 2021

Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

1 Apr 2021

Objectives, challenges and opportunities of new IASLC Molecular Database Project

A new Molecular Database Project initiated by the International Association for the Study of Lung will accelerate the understanding of lung cancer biology, clinical care and care delivery on a global scale and will improve the prognosis and optimal treatment of lung cancer across time and space, according to an editorial in the Journal of Thoracic Oncology, an official journal of the IASLC.

31 Mar 2021

Researchers explore a case of diabetic ketoacidosis in patient with atezolizumab-induced autoimmune diabetes

In a new publication from Cardiovascular Innovations and Applications, Sharen Lee and Gary Tse from Laboratory of Cardiovascular Physiology, Hong Kong, HKG, China, Second Hospital of Tianjin Medical University, Tianjin, China and Xiamen Cardiovascular Hospital, Xiamen, China consider a case of atezolizumab-induced autoimmune diabetes mellitus presenting with diabetic ketoacidosis.

29 Mar 2021

Checkpoint inhibition could offer an effective treatment option for patients with rare cancer

Peritoneal mesothelioma is cancer that develops in the lining of the abdomen, which is known as the peritoneum.

24 Mar 2021

Study characterizes shifting neoantigen burden between primary and metastatic tumors within HNSCC

Oncotarget published "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma" which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.

18 Mar 2021

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.

17 Mar 2021

Studies reveal how kidney tumors' microenvironments change in response to immunotherapy

In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer).

11 Mar 2021

Immune cells in cerebrospinal fluid could be novel biomarkers of response to immune-based therapies

Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.

8 Mar 2021

Compound isolated from Moroccan fungus shows promise to fight triple negative breast cancer

A compound isolated from a fungus growing on the roots of a flowering plant in Morocco shows promise as a powerful opponent of aggressive triple negative breast cancer, scientists say.

4 Mar 2021

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

3 Mar 2021

PICI awards $3 million to support early career cancer researchers

From improving immunotherapy response in childhood cancer patients, to better understanding how cancer's spread to the liver affects the body's immune system, to helping T cells stay energized to fight cancer, The Parker Institute for Cancer Immunotherapy (PICI)'s 2021 class of early career researchers award recipients are pursuing ideas that have the potential to change the face of oncology.

3 Mar 2021

Sequential administration of immunotherapy and targeted therapy prolongs anti-tumor responses

Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases.

2 Mar 2021

New technique uncovers the tricks used by cancer cells to evade immunotherapies

By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients--across cancer types--do not respond, and in most cases, scientists are at a loss as to why.

1 Mar 2021

Combination therapy produces clinical benefit for early stage non-small cell lung cancer

The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.

18 Feb 2021

Study: Targeted therapy prolongs survival in patients with advanced bladder cancer

In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

15 Feb 2021